The primary purpose of the Study is to compare the safety, tolerability and effectivenss of ruxolitinib with that of anagrelide in patients with essential thrombocythemia (ET) who are resistant or intolerant to Hydroxyurea.
Ruxolitinib is an investigational drug that is being studied in the treatment of ET. Ruxolitinib has been approved by the FDA under the trade name JAKAFI for the treatment of rare blood diorders called Myelofibrosis in 2011 and Polycythemia vera in 2014. It is a medication that blocks certain proteins called tyrosine kinases. It works by shutting down a pathway that is overactive in your disease. The medicine is take by mouth twice a day.
Anagrelide is a platelet-reducing medication and has been approved by the FDA for the treatment of patients with abnormally elevated platelet counts. Platelets are important for blood clotting.